Guidelines: Difference between revisions
Jump to navigation
Jump to search
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| (74 intermediate revisions by 3 users not shown) | |||
| Line 5: | Line 5: | ||
==== Prostate ==== | ==== Prostate ==== | ||
* [[AUA & ASTRO & SUO: | * '''<span style="color:#008000">NEW!</span>''' [[AUA & ASTRO & SUO: Salvage Therapy for Prostate Cancer (2024)|Salvage Therapy for Prostate Cancer (2024)]] | ||
*[[Advanced Prostate Cancer ( | * [[AUA: Advanced Prostate Cancer (2023)|Advanced Prostate Cancer (2023)]] | ||
* [[Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)]] | *[[AUA: Early Detection of Prostate Cancer (2023)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)]] | ||
* [[AUA: Prostate Cancer Screening (2018)|Prostate Cancer Screening (2018)]] | *[[AUA & ASTRO & SUO: Clinically Localized Prostate Cancer (2022)|Clinically Localized Prostate Cancer (2022)]] | ||
*[[Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)]] | |||
* [[AUA: Prostate Cancer Screening (2018)|Early Detection of Prostate Cancer/Prostate Cancer Screening (2018)]] | |||
* [[AUA: Clinically Localized Prostate Cancer (2017)|Clinically Localized Prostate Cancer (2017)]] | * [[AUA: Clinically Localized Prostate Cancer (2017)|Clinically Localized Prostate Cancer (2017)]] | ||
==== Bladder ==== | ==== Bladder ==== | ||
* [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]] | * '''<span style="color:#008000">NEW!</span>''' [[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2024)|Muscle-invasive Bladder Cancer (2024)]] | ||
*[[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2020)]] | |||
*[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]] | *[[Microscopic Hematuria (2020 AUA Guidelines)|Microscopic Hematuria (2020)]] | ||
*[[AUA & ASCO & ASTRO & SUO: Muscle-invasive Bladder Cancer (2020)|Muscle-invasive Bladder Cancer (2020)]] | |||
* [[Muscle-invasive Bladder Cancer (2017)]] | * [[Muscle-invasive Bladder Cancer (2017)]] | ||
* [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]] | * [[CUA/AUA: Non-muscle Invasive Bladder Cancer (2021 CUA/2016 AUA))|Non-muscle Invasive Bladder Cancer (2016)]] | ||
| Line 24: | Line 28: | ||
==== Testicular ==== | ==== Testicular ==== | ||
* (2019) Included in Testicular Tumours Chapter Notes | * (2019) Included in [https://test.urologyschool.com/index.php/Germ_Cell_Tumours Testicular Tumours Chapter Notes] | ||
==== Upper Tract Urothelial Carcinoma ==== | |||
* [[AUA: Upper Tract Urothelial Carcinoma (2023)|Upper Tract Urothelial Carcinoma (2023)]] | |||
=== Non-oncology === | === Non-oncology === | ||
| Line 30: | Line 37: | ||
==== Andrology ==== | ==== Andrology ==== | ||
* [[Testosterone Deficiency (2018)]] | * [[Priapism|Priapism (2021)]] | ||
* [[Erectile Dysfunction (2018)]] | *[[Testosterone Deficiency (2018)]] | ||
* [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2018)]] | |||
* [[Peyronie's Disease (2015)]] | * [[Peyronie's Disease (2015)]] | ||
==== Functional ==== | ==== Functional ==== | ||
* | * [[AUA: Female SUI (2023)|Female Stress Urinary Incontinence (2023)]] | ||
* AUA/CUA Mesh Position Statement (2019) | *[[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | ||
* Incontinence after Prostate Therapy (2019) | *'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]] | ||
* | *[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]] | ||
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]] | |||
==== Infertility ==== | |||
* AUA/ASRM Infertility (2020) included in Chapter Notes of | |||
** [[Infertility: Diagnosis and Evaluation|Diagnosis and Evaluation of Infertility]] | |||
** [[Infertility: Management|Management of Infertility]] | |||
==== Infections and Inflammation ==== | ==== Infections and Inflammation ==== | ||
* AUA/CUA Recurrent UTI (2019) | * [[AUA & CUA Recurrent UTI (2019)|AUA/CUA Recurrent UTI (2019)]] | ||
* | |||
==== Pediatrics ==== | |||
*[[AUA: Cryptorchidism (2018)|Cryptorchidism (2018)]] | |||
*[[AUA: Vesicoureteral Reflux (2017)|Vesicoureteral Reflux (2017)]] | |||
==== Stones ==== | ==== Stones ==== | ||
* Evaluation and Medical Management of Stones (2019) | * [[AUA: Evaluation and Medical Management of Stones (2019)|Evaluation and Medical Management of Stones (2019)]] | ||
* Stone Surgery (2016) | * [[AUA: Stone Surgery (2016)|Stone Surgery (2016)]] | ||
==== Other ==== | ==== Other ==== | ||
* Urotrauma (2020) | * [[AUA: Urethral Stricture Disease (2023)|Urethral Stricture Disease (2023)]] | ||
* Male Urethral Stricture (2016) | *'''<span style="color:#008000">NEW!</span>''' [[AUA: Interstitial Cystitis & Bladder Pain Syndrome (2022)|Interstitial Cystitis/Bladder Pain Syndrome (2022)]] | ||
* Vasectomy (2015) | *[[AUA: Urotrauma (2020)|Urotrauma (2020)]] | ||
* [[AUA: Male Urethral Stricture (2016)|Male Urethral Stricture (2016)]] | |||
* [[AUA & CUA: Vasectomy (AUA 2015, CUA 2016)|Vasectomy (2015)]] | |||
==== Contribute ==== | ==== Contribute ==== | ||
* BPH ( | * Overactive Bladder (2024) | ||
* | *Incontinence after Prostate Therapy (2024 Amendment) | ||
*Non-muscle Invasive Bladder Cancer (2024 Amendment) | |||
* | *Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment) | ||
* Antibiotic Prophylaxis (2019) | *Management of LUTS attributed to BPH (2023 Amendment) | ||
*[[AUA: Neurogenic LUTD (2021)|Neurogenic LUTD (2021)]] | |||
*Disorders of ejaculation (2020) | |||
* Antibiotic Prophylaxis (2019) | |||
== CUA Guidelines == | == CUA Guidelines == | ||
| Line 71: | Line 94: | ||
==== Prostate ==== | ==== Prostate ==== | ||
* Castrate-resistant Prostate Cancer (2021) | * [[CUA: Castrate-resistant Prostate Cancer (2021)|Castrate-resistant Prostate Cancer (2021)]] | ||
* Androgen Deprivation Therapy: Adverse Events & Management (2021) | * [[CUA: Androgen Deprivation Therapy: Adverse Events & Management (2021)|Androgen Deprivation Therapy: Adverse Events & Management (2021)]] | ||
* [[CUA: Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)|Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)]] | * [[CUA: Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)|Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)]] | ||
* Testosterone Suppression (2018) | * [[CUA: Testosterone Suppression (2018)|Testosterone Suppression (2018)]] | ||
* [[CUA: Prostate Cancer Screening (2017)|Prostate Cancer Screening (2017)]] | * [[CUA: Prostate Cancer Screening (2017)|Prostate Cancer Screening (2017)]] | ||
* Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017) | * [[Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)]] | ||
* Prostate Cancer Active Surveillance (2015) | * [[CUA: Prostate Cancer Active Surveillance (2015)|Prostate Cancer Active Surveillance (2015)]] | ||
==== Bladder ==== | ==== Bladder ==== | ||
* [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2021)]] | * [[CUA & AUA: Non-muscle Invasive Bladder Cancer (2021 CUA & 2020 AUA)|Non-muscle Invasive Bladder Cancer (2021)]] | ||
* Advanced and Metastatic Urothelial Cancer (2019) | * [[CUA: Advanced and Metastatic Urothelial Cancer (2019)|Advanced and Metastatic Urothelial Cancer (2019)]] | ||
* Muscle-invasive Bladder Cancer (2019) | * [[CUA: Muscle-invasive Bladder Cancer (2019)|Muscle-invasive Bladder Cancer (2019)]] | ||
* Asymptomatic | * [[CUA: Asymptomatic Microscopic Hematuria (2008)|Asymptomatic Microscopic Hematuria (2008)]] | ||
==== Kidney ==== | ==== Kidney ==== | ||
* Follow-up Localized RCC (2018) | * [[CUA: Follow-up Localized RCC (2018)|Follow-up Localized RCC (2018)]] | ||
* Cystic Renal Lesions (2017) | * [[CUA: Cystic Renal Lesions (2017)|Cystic Renal Lesions (2017)]] | ||
* Small Renal Masses (2015) | * [[CUA: Small Renal Masses (2015)|Small Renal Masses (2015)]] | ||
* Surgical Management of RCC (2014) | * [[CUA: Surgical Management of RCC (2014)|Surgical Management of RCC (2014)]] | ||
* [[CUA: RCC Genetic Screening (2013)|RCC Genetic Screening (2013)]] | * [[CUA: RCC Genetic Screening (2013)|RCC Genetic Screening (2013)]] | ||
| Line 98: | Line 121: | ||
==== Andrology ==== | ==== Andrology ==== | ||
* Peyronie's Disease (2018) | * [[CUA: Peyronie's Disease (2018)|Peyronie's Disease (2018)]] | ||
* Erectile Dysfunction (2021) | * [[AUA & CUA: Erectile Dysfunction (2021 CUA, 2018 AUA)|Erectile Dysfunction (2021)]] | ||
==== Functional ==== | ==== Functional ==== | ||
* Neurogenic Lower Urinary Tract Dysfunction (2019) | * [[CUA: Neurogenic Lower Urinary Tract Dysfunction (2019)|Neurogenic Lower Urinary Tract Dysfunction (2019)]] | ||
* Male LUTS/BPH (2018) | * [[CUA: Male LUTS & BPH (2018)|Male LUTS/BPH (2018)]] | ||
* CUA/AUA Mesh Position Statement (2019) | * [[AUA & CUA Mesh Position Statement (2019)|CUA/AUA Mesh Position Statement (2019)]] | ||
* Overactive Bladder (2017) | * [[CUA: Overactive Bladder (2017)|Overactive Bladder (2017)]] | ||
==== Infections and Inflammation ==== | ==== Infections and Inflammation ==== | ||
* CUA/AUA Recurrent UTI (2019) | * [[AUA & CUA Recurrent UTI (2019)|CUA/AUA Recurrent UTI (2019)]] | ||
* Antibiotic Prophylaxis (2015) | * [[CUA: Antibiotic Prophylaxis (2015)|Antibiotic Prophylaxis (2015)]] | ||
* Chronic Scrotal Pain (2018) | * [[CUA: Chronic Scrotal Pain (2018)|Chronic Scrotal Pain (2018)]] | ||
* Interstitial Cystitis (2016) | * [[CUA: Interstitial Cystitis (2016)|Interstitial Cystitis (2016)]] | ||
==== Infertility ==== | ==== Infertility ==== | ||
* Azoospermia (2015) | * [[CUA: Azoospermia (2015)|Azoospermia (2015)]] | ||
==== Pediatrics ==== | ==== Pediatrics ==== | ||
* Circumcision (2018) | * [[CUA: Circumcision (2018)|Circumcision (2018)]] | ||
* Antenatal hydronephrosis (2017) | * [[CUA: Antenatal hydronephrosis (2017)|Antenatal hydronephrosis (2017)]] | ||
* Cryptorchidism (2017) | * [[CUA: Cryptorchidism (2017)|Cryptorchidism (2017)]] | ||
* Multicystic Dysplastic Kidney in the Neonate (2015) | * [[CUA: Multicystic Dysplastic Kidney in the Neonate (2015)|Multicystic Dysplastic Kidney in the Neonate (2015)]] | ||
==== Stones ==== | ==== Stones ==== | ||
* Evaluation and Medical Management of Stones (2016) | * [[CUA: Evaluation and Medical Management of Stones (2016)|Evaluation and Medical Management of Stones (2016)]] | ||
* Ureteral Calculi (2015) | * [[CUA: Ureteral Calculi (2015)|Ureteral Calculi (2015)]] | ||
==== Other ==== | ==== Other ==== | ||
* Vasectomy ( | * [[AUA & CUA: Vasectomy (AUA 2015, CUA 2022)|Vasectomy (2022)]] | ||
* Adrenal Mass (2011) | * [[CUA: Adrenal Mass (2011)|Adrenal Mass (2011)]] | ||
* Radiation-induced Hemorrhagic Cystitis (2018) | * [[CUA: Radiation-induced Hemorrhagic Cystitis (2018)|Radiation-induced Hemorrhagic Cystitis (2018)]] | ||
* VTE Prophylaxis (2019) | * [[CUA: VTE Prophylaxis (2019)|VTE Prophylaxis (2019)]] | ||
*[[CUA: Vasectomy (2016)|Vasectomy (2016)]] | |||
==== Contribute ==== | ==== Contribute ==== | ||
* Ureteral calculi (2022) | *Ureteral calculi (2022) | ||
* Pediatric bladder dysfunction (2021) | * Pediatric bladder dysfunction (2021) | ||
* Sporadic angiomyolipomas (2020) | * Sporadic angiomyolipomas (2020) | ||
| Line 148: | Line 172: | ||
* Pheochromocytoma surveillance (2019) | * Pheochromocytoma surveillance (2019) | ||
* Pediatric hemorrhagic cystitis (2019) | * Pediatric hemorrhagic cystitis (2019) | ||
== Other Guidelines == | |||
=== '''<span style="color:#008000">NEW!</span>''' [[EAU & ASCO: Penile Cancer 2023|Penile Cancer (EAU/ASCO 2023)]] === | |||
Latest revision as of 17:35, 19 September 2024
AUA Guidelines[edit | edit source]
Oncology[edit | edit source]
Prostate[edit | edit source]
- NEW! Salvage Therapy for Prostate Cancer (2024)
- Advanced Prostate Cancer (2023)
- Early Detection of Prostate Cancer/Prostate Cancer Screening (2023)
- Clinically Localized Prostate Cancer (2022)
- Adjuvant and Salvage Radiotherapy After Prostatectomy (2019)
- Early Detection of Prostate Cancer/Prostate Cancer Screening (2018)
- Clinically Localized Prostate Cancer (2017)
Bladder[edit | edit source]
- NEW! Muscle-invasive Bladder Cancer (2024)
- Non-muscle Invasive Bladder Cancer (2020)
- Microscopic Hematuria (2020)
- Muscle-invasive Bladder Cancer (2020)
- Muscle-invasive Bladder Cancer (2017)
- Non-muscle Invasive Bladder Cancer (2016)
Kidney[edit | edit source]
Testicular[edit | edit source]
- (2019) Included in Testicular Tumours Chapter Notes
Upper Tract Urothelial Carcinoma[edit | edit source]
Non-oncology[edit | edit source]
Andrology[edit | edit source]
- Priapism (2021)
- Testosterone Deficiency (2018)
- Erectile Dysfunction (2018)
- Peyronie's Disease (2015)
Functional[edit | edit source]
- Female Stress Urinary Incontinence (2023)
- Management of LUTS Attributed to BPH (2021)
- NEW! Overactive Bladder (2019)
- AUA/CUA Mesh Position Statement (2019)
- Incontinence after Prostate Therapy (2019)
Infertility[edit | edit source]
- AUA/ASRM Infertility (2020) included in Chapter Notes of
Infections and Inflammation[edit | edit source]
Pediatrics[edit | edit source]
Stones[edit | edit source]
Other[edit | edit source]
- Urethral Stricture Disease (2023)
- NEW! Interstitial Cystitis/Bladder Pain Syndrome (2022)
- Urotrauma (2020)
- Male Urethral Stricture (2016)
- Vasectomy (2015)
Contribute[edit | edit source]
- Overactive Bladder (2024)
- Incontinence after Prostate Therapy (2024 Amendment)
- Non-muscle Invasive Bladder Cancer (2024 Amendment)
- Diagnosis and Treatment of Early Stage Testicular Cancer (2024 Amendment)
- Management of LUTS attributed to BPH (2023 Amendment)
- Neurogenic LUTD (2021)
- Disorders of ejaculation (2020)
- Antibiotic Prophylaxis (2019)
CUA Guidelines[edit | edit source]
Oncology[edit | edit source]
Prostate[edit | edit source]
- Castrate-resistant Prostate Cancer (2021)
- Androgen Deprivation Therapy: Adverse Events & Management (2021)
- Metastatic Castration-naive and Castration-sensitive Prostate Cancer (2020)
- Testosterone Suppression (2018)
- Prostate Cancer Screening (2017)
- Cancer Care Ontario: MRI in Prostate Cancer Diagnosis (2017)
- Prostate Cancer Active Surveillance (2015)
Bladder[edit | edit source]
- Non-muscle Invasive Bladder Cancer (2021)
- Advanced and Metastatic Urothelial Cancer (2019)
- Muscle-invasive Bladder Cancer (2019)
- Asymptomatic Microscopic Hematuria (2008)
Kidney[edit | edit source]
- Follow-up Localized RCC (2018)
- Cystic Renal Lesions (2017)
- Small Renal Masses (2015)
- Surgical Management of RCC (2014)
- RCC Genetic Screening (2013)
Non-oncology[edit | edit source]
Andrology[edit | edit source]
Functional[edit | edit source]
- Neurogenic Lower Urinary Tract Dysfunction (2019)
- Male LUTS/BPH (2018)
- CUA/AUA Mesh Position Statement (2019)
- Overactive Bladder (2017)
Infections and Inflammation[edit | edit source]
- CUA/AUA Recurrent UTI (2019)
- Antibiotic Prophylaxis (2015)
- Chronic Scrotal Pain (2018)
- Interstitial Cystitis (2016)
Infertility[edit | edit source]
Pediatrics[edit | edit source]
- Circumcision (2018)
- Antenatal hydronephrosis (2017)
- Cryptorchidism (2017)
- Multicystic Dysplastic Kidney in the Neonate (2015)
Stones[edit | edit source]
Other[edit | edit source]
- Vasectomy (2022)
- Adrenal Mass (2011)
- Radiation-induced Hemorrhagic Cystitis (2018)
- VTE Prophylaxis (2019)
- Vasectomy (2016)
Contribute[edit | edit source]
- Ureteral calculi (2022)
- Pediatric bladder dysfunction (2021)
- Sporadic angiomyolipomas (2020)
- Male urethral stricture (2020)
- Catheter use (2020)
- Renal mass biopsy (2019)
- Pheochromocytoma surveillance (2019)
- Pediatric hemorrhagic cystitis (2019)